Young biotechnology companies find themselves in a tougher spot today than they did two years ago.
Initial public offerings are no longer the sure thing they were in 2021. Private financing rounds are harder to raise. Investors are more cautious, and layoffs have become common as companies run low on cash.
Copyright © 2023,